TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01802671

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioural therapy (CBT)
Description: Patients will receive the same treatment in physical therapy than the control group and additionally they will receive CBT. The aim of the CBT intervention is to produce changes in the beliefs and behaviors about physical activity and avoidance of activity. The treatment's components are:~* Psychoeducation to counteract the misconceptions about low back pain and to point on the relevance of maintaining an adequate level of activity.~* Cognitive restructuring techniques~* Behavioural therapy and activity pacing~* Training on self-management pain techniques (mindfulness and relaxation). It is a 6-session group therapy, with one session per week. Each group will be composed by 6-8 participants. It will be considered as a patient who receives the treatment when the patient attends to the assessment sessions and to at least 4 out of 6 CBT sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioural therapy (CBT)
Description: Patients will receive the same treatment in physical therapy than the control group and additionally they will receive CBT. The aim of the CBT intervention is to produce changes in the beliefs and behaviors about physical activity and avoidance of activity. The treatment's components are:~* Psychoeducation to counteract the misconceptions about low back pain and to point on the relevance of maintaining an adequate level of activity.~* Cognitive restructuring techniques~* Behavioural therapy and activity pacing~* Training on self-management pain techniques (mindfulness and relaxation). It is a 6-session group therapy, with one session per week. Each group will be composed by 6-8 participants. It will be considered as a patient who receives the treatment when the patient attends to the assessment sessions and to at least 4 out of 6 CBT sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behaviour therapy supported by ICT
Description: The patients of this group will receive the same interventions that the CBT group but will receive a reinforcements of the sessions' content through two different ways, both based on ICTs: a web tool named TEO (Emotional Therapy Online) specially designed to practicing the therapeutic strategies at home; and SMS that will send to the patients' mobile phone with reminders and reinforcements. The content of sessions will be related to the therapeutic components including on the CBT. Patients will access TEO from their home using a personal password. Besides TEO, messages will be sent through SMS three times per week during the treatment and once a week during the follow-up. The messages will consist on reminders to do the homework along with reinforcements of the working and effort made to improve their health.
Study: NCT00807872

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 124I-labeled monoclonal antibody Mu 11-1F4
Description: Single infusion of radiolabeled antibody: 2 mCi (1 mg)
Study: NCT00088153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Physiologic Estrogen/progesterone
Description: Vivelle Dot patch 100 mcg twice weekly; Provera 2.5 mg daily for the first 10 days of the month

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo patches twice weekly; Placebo pills daily for the first 10 days of every month
Study: NCT02749929

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low level laser therapy
Description: The laser is an infrared (invisible) 60 mW 904 nm Irradia Midlaser

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Low Level Laser Therapy
Description: The placebo laser is an identical device to the active laser, made by Irradia Midlaser
Study: NCT02122276

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ankle continuous passive motion machine.
Description: A rehabilitation program of machine driven passive stretch exercise on ankle.
Study: NCT02128750

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: contrast echographie with hexafluorur of sulfur
Description: Echography of contrast after injection of product of contrast (sonovue (r))
Study: NCT04541654

Intervention type: GENETIC
Intervention: Data and Specimen Collection
Description: * Provide research team and access to relevant medical records~* Answer short questionnaires periodically~* Consider consenting to other optional parts of the research such as:~* Providing up to 3 tubes (15ml) of blood at or near the time of consent, as approved by treating physician (optional).~* Provide a saliva sample (optional).~* Provide eyebrow hairs for analysis of DNA from the bulb (15-20 eyebrow plucks) (optional).~* Provide permission for obtainment of stored tissue specimens from cancer or pre-cancer surgeries or biopsies from the pathology departments where they have been stored (optional).~* Consider inviting relatives to join the study (optional).
Study: NCT02891824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atezolizumab + avastin + platinum-based chemotherapy
Description: * atezolizumab will be administrated by intraveinous route at dose of 1200 mg or 800 mg during the induction period and will be continued in maintenance period at a dose of 1200mg until progression~* avastin will be administrated by intraveinous route at dose of 15mg/kg or 10 mg/kg during the induction period and will be continued in maintenance period of at a dose of 15mg/kg until progression~* platinum-based chemotherapy (Carboplatin combined with gemcitabine or paclitaxel or pegylated liposomal doxorubicin) will be administrated by intraveinous route at different doses during the induction period x 6 cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo + avastin + platinum-based chemotherapy
Description: * placebo will be administrated by intraveinous route at dose of 1200 mg or 800 mg during the induction period and will be continued in maintenance period at a dose of 1200mg until progression~* avastin will be administrated by intraveinous route at dose of 15mg/kg or 10 mg/kg during the induction period and will be continued in maintenance period of at a dose of 15mg/kg until progression~* platinum-based chemotherapy (Carboplatin combined with gemcitabine or paclitaxel or pegylated liposomal doxorubicin) will be administrated by intraveinous route at different doses during the induction period x 6 cycles
Study: NCT02555241

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Matrix
Description: The matrix training component of treatment will consist of behavioral principles designed to teach labeling of noun-verb and color-shape combinations using matrix training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stimulus Equivalence Training
Description: The stimulus equivalence training component of treatment is designed to examine the emergence of untrained skills following the training of relational skills.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stimulus Equivalence Training
Description: The stimulus equivalence training component of treatment is designed to examine the emergence of untrained skills following the training of relational skills.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stimulus Equivalence Training
Description: The stimulus equivalence training component of treatment is designed to examine the emergence of untrained skills following the training of relational skills.
Study: NCT04077398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% Injectable Solution
Description: There will be two groups, in order to compare two different sets of volumes with the same amount of drug. we will try to identify if it is better one volume over the other in terms of pain control and consume of opioids, as well the presence or absence of motor weakness.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% Injectable Solution
Description: There will be two groups, in order to compare two different sets of volumes with the same amount of drug. we will try to identify if it is better one volume over the other in terms of pain control and consume of opioids, as well the presence or absence of motor weakness.
Study: NCT02699697

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT
Study: NCT02387918

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Patients will receive Intravenous dexamethasone 0.15 mg/kg immediately after induction of anesthesia.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture treatment (just after induction of anaesthesia and for approximately 20 minutes)
Study: NCT03185351

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 20 ml of 0.5% bupivacaine using supraclavicular BPB.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 20 ml of 0.5% bupivacaine using supraclavicular BPB.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 20 ml of 0.5% bupivacaine using supraclavicular BPB.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: midazolam 0.03 mg/kg dissolved in 5 ml normal saline (0.9%) using supraclavicular BPB

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: 0.03 mg/kg of midazolam by I.V. route
Study: NCT01779661

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infant Aquatics
Description: Infant Aquatics in this study is composed of a set of pre-structured movements and techniques of relaxation, through harmonic integration of various approaches, each having a role in a specific time-window or in the infant's developmental sequence along study interventional timeline

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infant Massage
Description: Infant Massage
Study: NCT01509105

Intervention type: BIOLOGICAL
Intervention: 13-valent pneumococcal vaccine
Description: 0.5mL IM (Intramuscular administration) as per recommended schedule
Study: NCT04058301

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text message information
Description: Geographically proximate resources delivered by text message
Study: NCT03090269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate Pill
Description: 3-month follow-up to study the effective dose as a treatment for cocaine dependence in toxicity and reduction in cocaine use
Study: NCT01580748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: 500 microgram once daily for 16 weeks
Study: NCT02558751

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 23-valent pneumococcal polysaccharide vaccine
Description: One standard adult dose of the 23-valent pneumococcal polysaccharide vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 23-valent pneumococcal polysaccharide vaccine
Description: One standard adult dose of the 23-valent pneumococcal polysaccharide vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 23-valent pneumococcal polysaccharide vaccine
Description: One standard adult dose of the 23-valent pneumococcal polysaccharide vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13-valent pneumococcal conjugate vaccine
Description: One dose of the 13-valent pneumococcal conjugate vaccine, PCV13, followed 8 weeks later by one dose of the 23-valent pneumococcal polysaccharide vaccine, PPV23.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13-valent pneumococcal conjugate vaccine
Description: One dose of the 13-valent pneumococcal conjugate vaccine, PCV13, followed 8 weeks later by one dose of the 23-valent pneumococcal polysaccharide vaccine, PPV23.
Study: NCT02340273

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound
Description: Patients receive therapeutic ultrasound daily for 4 hours of continuous therapy at 3 megahertz (MHz) frequency and 0.132 Watts/cm2.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo therapeutic ultrasound
Description: Patients receive sham therapeutic ultrasound daily for 4 hours.
Study: NCT03608332

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: diaphragmatic ultrasound
Description: Diaphragmatic excursion; Diaphragmatic movement will be measured with a 3.5-MHz US probe (Mindray machine, DC-N6).
Study: NCT01327703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panzytrat® 25,000
Description: Panzytrat® 25,000 capsule will be given orally daily at a stabilized dose, as per investigator's discretion, for 14 days. Stabilized dose for a participant will be the optimal dose determined during a qualification phase that precedes the first treatment period and will be based upon the participant's usual lipase and lipid intake. Total dose will not exceed 10,000 European Pharmacopoeia (Ph.Eur.) units lipase/kilogram (kg) body weight/day in either first treatment period or second treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kreon® 25,000
Description: Kreon® 25,000 capsule will be given orally daily at a stabilized dose, as per investigator's discretion, for 14 days. Stabilized dose for a participant will be the optimal dose determined during a qualification phase that precedes the first treatment period and will be based upon the participant's usual lipase and lipid intake. Total dose will not exceed 10,000 Ph.Eur. units lipase/kg body weight/day in either first treatment period or second treatment period.
Study: NCT02705157

Intervention type: PROCEDURE
Intervention: Stabilisation of (impending) pathological fracture
Description: Stabilisation of pathological fracture or impending fracture with prosthesis, plate, intramedullary nail, cement, or other stabilisation method

Intervention type: RADIATION
Intervention: Radiotherapy of bone metastasis
Description: Radiotherapy of bone metastasis, single or multi-fractionated
Study: NCT04227717

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI with custom MRI spine coil
Description: Participants will undergo MRI with custom MRI spine coil
Study: NCT04124796

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Semi-structured interviews
Description: Based on an interview grid previously built, the interviews will investigate the factors governing the decision to consult and methods of intervention to reduce the time to consult.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Semi-structured interviews
Description: Based on an interview grid previously built, the interviews will investigate the factors governing the decision to consult and methods of intervention to reduce the time to consult.
Study: NCT00728923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPL-2003
Description: Minocycline (NPL-2003) daily for 12 weeks
Study: NCT02129556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: The phase Ib trial will determine the recommended dose from three MK-3475 dose levels: 1mg/kg, 2 mg/kg or 10 mg/kg.
Study: NCT01910532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clevidipine
Description: Clevidipine for the treatment of acute hypertension defined SBP \> 160 mmHg in patients who require an Intracranial Pressure Monitoring Device
Study: NCT01150331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam/Clonazepam
Description: Association of two anti-epileptic drugs in first line

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonazepam/Placebo levetiracetam IV
Description: Association of placebo to an active comparator (clonazepam)
Study: NCT05538819

Intervention type: DRUG
Intervention: Glimepiride
Description: Glimepiride 1-4 mg/day
Study: NCT04050917

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real stimulation
Description: The smartwatch generates imperceptible vibratory stimulation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: no stimulation
Description: The smartwatch generates no stimulation.
Study: NCT03620656

Intervention type: DIAGNOSTIC_TEST
Intervention: FibriCheck
Description: Photoplethysmography-based smartphone or smartwatch sensor to assess cardiac rhythm

Intervention type: DIAGNOSTIC_TEST
Intervention: FibriCheck
Description: Photoplethysmography-based smartphone or smartwatch sensor to assess cardiac rhythm
Study: NCT04571515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MR-107A-01
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MR-107A-01
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MR-107A-01
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MR-107A-01
Description: Oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet
Study: NCT00931840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EZN-2208, Cetuximab and Irinotecan
Description: Patients with mutated K RAS tumors will be treated with single-agent EZN-2208 (Arm A). PLEASE NOTE THAT ENROLLMENT IN EXPERIMENTAL ARM (ARM A) IS COMPLETE. NO NEW PATIENT IN THIS ARM IS ALLOWED TO ENROLL.~Patients with wild-type K-RAS tumors will be randomly assigned in a 2:1 ratio to EZN-2208 + cetuximab (Arm B) or the benchmark of irinotecan + cetuximab (Arm C).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EZN-2208, Cetuximab and Irinotecan
Description: Patients with mutated K RAS tumors will be treated with single-agent EZN-2208 (Arm A). PLEASE NOTE THAT ENROLLMENT IN EXPERIMENTAL ARM (ARM A) IS COMPLETE. NO NEW PATIENT IN THIS ARM IS ALLOWED TO ENROLL.~Patients with wild-type K-RAS tumors will be randomly assigned in a 2:1 ratio to EZN-2208 + cetuximab (Arm B) or the benchmark of irinotecan + cetuximab (Arm C).
Study: NCT02891330

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary and nutritional recommendations conducted by a nurse
Description: Supplementary dietary and nutritional education
Study: NCT02699697

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Palliative Radiation Therapy
Description: Undergo EBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Palliative Radiation Therapy
Description: Undergo EBRT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT00931840

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EZN-2208, Cetuximab and Irinotecan
Description: Patients with mutated K RAS tumors will be treated with single-agent EZN-2208 (Arm A). PLEASE NOTE THAT ENROLLMENT IN EXPERIMENTAL ARM (ARM A) IS COMPLETE. NO NEW PATIENT IN THIS ARM IS ALLOWED TO ENROLL.~Patients with wild-type K-RAS tumors will be randomly assigned in a 2:1 ratio to EZN-2208 + cetuximab (Arm B) or the benchmark of irinotecan + cetuximab (Arm C).
Study: NCT03798899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxyflurane
Description: PENTHROX 3mL inhalation vapour, liquid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Placebo
Study: NCT02699697

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04161456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Apremilast twice daily 30 mg
Study: NCT04403633

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobile health educational tool
Description: Interactive educational tool delivered on iPad
Study: NCT01419444

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Airflow Exercises for Voicing
Description: Gargling, Cup Bubble Blowing, and Stretch and Flow Exercises will be taught to reduce laryngeal closure and improve airflow through the glottis during voicing.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Airflow Exercises for Voicing
Description: Gargling, Cup Bubble Blowing, and Stretch and Flow Exercises will be taught to reduce laryngeal closure and improve airflow through the glottis during voicing.
Study: NCT01742676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADVAGRAF
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PROGRAF
Description: oral
Study: NCT04445974

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Expand your horizons: More than my skin
Description: 'Expand Your Horizon' is a self-help intervention which uses writing exercises to help individuals with poor body image practice focusing on their body-functionality rather than their physical appearance (Alleva et al., 2015). The materials for 'Expand Your Horizon' are freely available (Alleva et al., 2015), and permission has been granted to use and adapt the materials in this research. 'Expand Your Horizon' comprises of three 15 min writing exercises, typically completed over approximately six days. The intervention materials have been adapted for use with a population with skin diseases, and modified to use gender neutral language. Adaptions were made in consultation with experts by experience. The changes were reviewed and approved by the first author of the original intervention to ensure the materials were in keeping with the original intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Creative writing activities
Description: In line with previous studies examining 'Expand Your Horizon' the active control condition will involve creative writing tasks (Alleva et al., 2015). Participants in the intervention condition will complete three 15 minute creative writing exercises, completed over six days.
Study: NCT02699697

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT00433537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study: NCT04215003

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A
Description: Paclitaxel: paclitaxel 80 mg/m2 ivgtt d1, d8, d15, 28 days per cycle. Carboplatin: carboplatin AUC=2 ivgtt d1, d8, d15, 28 days per cycle. Herceptin: 4 mg/kg (loading dose 8mg/kg) ivgtt d1,8,15, 22, 28 days per cycle,6 cycles.~Pertuzumab: 420-mg ( loading dose 840mg) ivgtt d1, 21 days per cycle,6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B
Description: Paclitaxel: paclitaxel 80 mg/m2 ivgtt d1, d8, d15, 28 days per cycle. Carboplatin: carboplatin AUC=2 ivgtt d1, d8, d15, 28 days per cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CL4
Description: SHR6390（CDK4/6 inhibitor）125 mg qd(three week on one week off); oral letrozole 2.5 mg daily； Adebrelimab was given intravenously, 600mg each time, once every 2 weeks; Premenopause：Goserelin 3.6mg IM IM Q4W.
Study: NCT03760939

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical and economical evaluation
Description: Evaluation of the clinical and the economical impact of a colorectal surgery

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical and economical evaluation
Description: Evaluation of the clinical and the economical impact of a colorectal surgery